CJC-1295 & Ipamorelin Blend (10mg) – Research Peptide

CJC-1295 & Ipamorelin Blend (10mg) is an experimental peptide formulation combining two synthetic peptides investigated in connection with growth-hormone signalling and pituitary research.

The referenced product contains 5mg CJC-1295 No DAC and 5mg Ipamorelin, providing a total peptide content of 10mg. It is supplied as a lyophilised powder with a stated purity of >99%.

CJC-1295 No DAC, commonly associated with Mod GRF 1-29, is studied as a modified analogue related to growth-hormone-releasing hormone (GHRH). Ipamorelin is a synthetic pentapeptide investigated as a growth-hormone secretagogue associated with the growth-hormone secretagogue receptor (GHS-R1a). The two peptides therefore provide researchers with an experimental model for examining complementary pathways involved in pituitary growth-hormone regulation.

The combination is of scientific interest because GHRH-related signalling and GHS-R1a signalling represent distinct mechanisms that can converge on growth-hormone release. However, research involving individual compounds or related peptide combinations should not be interpreted as proof of efficacy or safety for this exact 10mg formulation.

---

What Is CJC-1295 & Ipamorelin Blend?

The CJC-1295 & Ipamorelin Blend is a two-component experimental peptide formulation intended for laboratory research into endocrine signalling, pituitary biology and growth-hormone pathways.

The referenced formulation contains:

• 5mg CJC-1295 No DAC
• 5mg Ipamorelin
• 10mg total peptide content
• 1:1 ratio by stated mass
• Lyophilised powder format
• >99% stated purity

The product listing identifies CJC-1295 as CJC-1295 No DAC, also known in research contexts as Modified GRF 1-29. It identifies Ipamorelin as the second component of the blend.

---

CJC-1295 No DAC – Research Profile

CJC-1295 No DAC is commonly referred to as Modified GRF 1-29 or Mod GRF 1-29. It is a synthetic peptide related to the first 29 amino acids of growth-hormone-releasing hormone.

GHRH is naturally involved in the regulation of growth-hormone secretion from somatotroph cells in the anterior pituitary. Research into Modified GRF 1-29 therefore focuses on the GHRH receptor pathway and the mechanisms through which GHRH-related peptides influence pituitary signalling.

The “No DAC” designation is particularly important. It distinguishes this preparation from CJC-1295 formulations incorporating a Drug Affinity Complex (DAC). Researchers should therefore verify the precise form of CJC-1295 when comparing experimental data.

The referenced Core Peptides listing specifically identifies the CJC-1295 component as No DAC.

---

Ipamorelin – Research Profile

Ipamorelin is a synthetic pentapeptide investigated as a growth-hormone secretagogue. Scientific literature has characterised Ipamorelin as a selective growth-hormone secretagogue associated with the GHS-R1a receptor.

GHS-R1a is commonly known as the growth-hormone secretagogue receptor and is closely associated with ghrelin signalling. Research into this receptor system has helped establish an additional pathway through which growth-hormone release can be regulated.

Research interest in Ipamorelin includes its receptor selectivity and its effects on pituitary growth-hormone signalling. An early pharmacological study described Ipamorelin as a selective growth-hormone secretagogue and investigated its endocrine activity in experimental models.

---

CJC-1295 & Ipamorelin Blend – Product Highlights

• Product name: CJC-1295 & Ipamorelin Blend
• Total quantity: 10mg
• CJC-1295 No DAC: 5mg
• Ipamorelin: 5mg
• Blend ratio: 1:1 by stated mass
• Form: Lyophilised powder
• Stated purity: >99%
• Primary research area: Growth-hormone and pituitary biology
• Research pathways: GHRH receptor and GHS-R1a signalling
• Classification: Experimental peptide blend
• Intended purpose: Laboratory research

---

CJC-1295 & Ipamorelin Chemical Profile

Property	CJC-1295 No DAC	Ipamorelin
Common designation	Mod GRF 1-29	Ipamorelin
Quantity	5mg	5mg
Total blend	10mg
Blend ratio	1:1 by stated mass
General classification	GHRH-related analogue	Growth-hormone secretagogue
Research-associated receptor	GHRH receptor	GHS-R1a
Physical form	Lyophilised powder
Stated purity	>99%

---

How CJC-1295 and Ipamorelin Differ

Although both peptides are investigated in connection with growth-hormone regulation, they are structurally and pharmacologically distinct.

Feature	CJC-1295 No DAC	Ipamorelin
Peptide type	Modified GHRH-related peptide	Synthetic pentapeptide
Research classification	GHRH analogue	Growth-hormone secretagogue
Primary research pathway	GHRH receptor	GHS-R1a
Research focus	GHRH-related pituitary signalling	Secretagogue-mediated signalling

The different receptor systems are central to the scientific rationale for investigating these peptides together. Research into growth-hormone secretagogues has established GHS-R as a distinct neuroendocrine pathway involved in pulsatile GH release.

---

Why Combine CJC-1295 and Ipamorelin?

The primary research rationale for combining CJC-1295 No DAC and Ipamorelin is the investigation of complementary signalling mechanisms.

CJC-1295 No DAC is associated with the GHRH receptor pathway, while Ipamorelin is associated with the GHS-R1a pathway. These pathways are different but can converge on the regulation of growth-hormone secretion by pituitary somatotroph cells.

This makes the combination scientifically relevant for experimental studies examining how simultaneous stimulation of different receptor systems influences pituitary signalling.

Core Peptides itself describes the two peptides as potentially complementary in research contexts but also acknowledges that direct research investigating the exact blend remains limited.

Consequently, the existence of complementary pathways should not be presented as proof that the commercial 10mg blend produces a particular clinical effect.

---

Growth-Hormone Axis Research

The growth-hormone axis involves a complex network of hormonal signals connecting the hypothalamus, pituitary gland and peripheral tissues.

Important components include:

• GHRH: A hypothalamic hormone involved in stimulating pituitary growth-hormone release.
• Somatostatin: An inhibitory regulator of GH secretion.
• GHS-R1a: A receptor associated with ghrelin and synthetic growth-hormone secretagogues.
• Growth hormone: A pituitary hormone involved in numerous physiological processes.
• IGF-1: A downstream growth factor associated with GH signalling.

Research into CJC-1295 and Ipamorelin provides an experimental framework for examining two upstream mechanisms involved in this wider endocrine system.

---

CJC-1295 No DAC and GHRH Signalling

GHRH is produced in the hypothalamus and contributes to the regulation of growth-hormone secretion by the anterior pituitary.

Modified GRF 1-29 is designed around the biologically active region of GHRH. Researchers have investigated modifications to this peptide sequence in relation to stability, receptor interaction and biological activity.

The CJC-1295 No DAC component in this blend is therefore relevant to research examining GHRH receptor activation and somatotroph signalling.

---

Ipamorelin and GHS-R1a Research

Ipamorelin is investigated primarily as a growth-hormone secretagogue associated with GHS-R1a.

Growth-hormone secretagogues form a distinct signalling system. Research into the GHS receptor has demonstrated its presence in the pituitary and hypothalamus and its role in regulating pulsatile GH release.

Ipamorelin is of particular research interest because it has been characterised as a relatively selective secretagogue. An early study described Ipamorelin as a potent growth-hormone-releasing compound with selectivity in its endocrine activity.

---

CJC-1295 No DAC vs CJC-1295 With DAC

The distinction between CJC-1295 No DAC and CJC-1295 with DAC is important when interpreting scientific literature.

Feature	CJC-1295 No DAC / Mod GRF 1-29	CJC-1295 With DAC
Drug Affinity Complex	Absent	Present
General classification	Modified GHRH-related peptide	Modified longer-acting CJC-1295 preparation
Research consideration	Should be evaluated independently	Different pharmacokinetic characteristics

The product referenced here contains CJC-1295 No DAC. Researchers should therefore avoid treating findings from DAC-containing CJC-1295 preparations as directly equivalent to results obtained with Mod GRF 1-29.

---

Research Interest in Peptide Synergy

The term synergy is sometimes used to describe a situation in which combined biological activity exceeds the expected activity of the individual components.

For CJC-1295 and Ipamorelin, the scientific hypothesis centres on their association with different receptor systems. CJC-1295 No DAC is linked to GHRH receptor signalling, while Ipamorelin is linked to GHS-R1a signalling.

Because both pathways are involved in growth-hormone regulation, researchers may investigate whether simultaneous stimulation produces different responses from either peptide alone.

However, a theoretical mechanism is not sufficient to establish synergy. Demonstrating synergy requires controlled experiments comparing individual and combined exposures using appropriate experimental controls and validated endpoints.

---

Potential Research Applications

The CJC-1295 & Ipamorelin Blend may be relevant to laboratory research involving:

• Pituitary biology: Investigation of somatotroph-cell signalling.
• Growth-hormone research: Study of mechanisms involved in GH secretion.
• GHRH receptor research: Investigation of Mod GRF 1-29 and related signalling.
• GHS-R1a research: Study of growth-hormone-secretagogue receptor activity.
• Peptide pharmacology: Comparison of different endocrine-active peptides.
• Receptor interaction studies: Investigation of complementary signalling pathways.
• Endocrine research: Study of the broader GH regulatory system.
• GH–IGF-1 research: Investigation of relationships between GH and downstream signalling.
• Analytical research: Peptide identity, purity and stability testing.

---

Understanding the 10mg Formulation

The 10mg designation refers to the total peptide content of the referenced product.

• 5mg CJC-1295 No DAC
• 5mg Ipamorelin

The formulation therefore contains the two components in a stated 1:1 ratio by mass. The 10mg quantity is a product specification and should not be interpreted as a human dosage or treatment recommendation.

---

Lyophilised Peptide Format

The product is supplied as a lyophilised powder. Lyophilisation, commonly known as freeze-drying, is widely used for laboratory peptide preparations.

A dry peptide preparation can facilitate laboratory storage, handling and analytical characterisation when appropriate research procedures are followed. Researchers should refer to batch-specific documentation and applicable laboratory protocols when handling experimental peptide materials.

---

Analytical Quality and Purity

Accurate peptide research depends on reliable identification and characterisation of the experimental material.

Common analytical approaches include:

• HPLC: Used to assess chromatographic purity.
• Mass spectrometry: Used to support molecular identity and molecular-mass determination.
• Certificate of Analysis: Provides batch-specific analytical information where available.
• Lot tracking: Supports traceability and experimental reproducibility.

The referenced Core Peptides product listing states a purity of >99% for the 10mg blend.

---

Research Evidence for Ipamorelin

Ipamorelin has been investigated as a selective growth-hormone secretagogue. A peer-reviewed study published in the European Journal of Endocrinology characterised Ipamorelin as a novel growth-hormone secretagogue and examined its endocrine activity.

Research into the GHS receptor system has also established that synthetic growth-hormone secretagogues act through a receptor pathway located in the pituitary and hypothalamus. This pathway contributes to the control of pulsatile GH release.

These findings provide scientific context for studying Ipamorelin, but they do not establish clinical efficacy or long-term safety for an unapproved peptide blend.

---

Research Evidence for CJC-1295

CJC-1295 has been investigated as a modified GHRH-related peptide. Research has examined its interactions with GHRH-related pathways, pharmacological characteristics and effects on growth-hormone signalling.

The precise properties of CJC-1295 No DAC should nevertheless be distinguished from those of DAC-containing CJC-1295 preparations. Studies of one formulation cannot automatically be transferred to another.

This distinction is particularly important when evaluating research that reports prolonged pharmacokinetic behaviour for CJC-1295 formulations incorporating the Drug Affinity Complex.

---

Research Into CJC-1295 and Ipamorelin Together

The scientific rationale for combining the two peptides comes from their different signalling pathways.

CJC-1295 No DAC is associated with the GHRH receptor, while Ipamorelin is associated with GHS-R1a. These receptors represent separate pathways involved in regulating pituitary growth-hormone release.

Core Peptides’ own research discussion notes that there is currently limited direct research investigating the exact CJC-1295 and Ipamorelin blend, and presents the combination primarily as a subject for further laboratory investigation.

Accordingly, the blend should be described as an experimental research formulation, rather than as a clinically established combination.

---

Research Limitations

Several important limitations should be considered when evaluating this peptide blend:

• Limited direct blend research: Evidence concerning the exact 10mg formulation remains limited.
• Different CJC-1295 forms: No-DAC and DAC-containing preparations have different properties and should be assessed separately.
• Individual peptide evidence: Results from one component do not automatically establish the effects of the combined formulation.
• Experimental status: Laboratory and animal findings cannot automatically be translated into human therapeutic outcomes.
• Long-term safety: The long-term safety profile of unapproved peptide combinations remains insufficiently characterised.
• Endocrine complexity: Manipulating growth-hormone signalling may influence multiple physiological pathways.

---

Frequently Asked Questions About CJC-1295 & Ipamorelin Blend (10mg)

What is CJC-1295 & Ipamorelin Blend (10mg)?

It is an experimental peptide formulation containing 5mg CJC-1295 No DAC and 5mg Ipamorelin, providing a total of 10mg of peptide material.

What is the ratio of CJC-1295 to Ipamorelin?

The referenced formulation contains a stated 1:1 ratio by mass, with 5mg of each peptide.

What is CJC-1295 No DAC?

CJC-1295 No DAC is commonly associated with Modified GRF 1-29 and is studied as a synthetic GHRH-related peptide involved in research into pituitary growth-hormone signalling.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide investigated as a growth-hormone secretagogue associated with the GHS-R1a receptor.

Why are CJC-1295 and Ipamorelin combined?

The two peptides are associated with different signalling pathways involved in growth-hormone regulation. Their combination provides an experimental model for investigating potential interactions between GHRH-related and GHS-R1a signalling.

What does the 10mg specification mean?

It refers to the total peptide quantity in the product: 5mg CJC-1295 No DAC plus 5mg Ipamorelin.

Is CJC-1295 No DAC the same as CJC-1295 with DAC?

No. The No-DAC and DAC-containing forms have different characteristics. The product referenced here specifically contains CJC-1295 No DAC.

What form is the product supplied in?

The referenced product is supplied as a lyophilised powder.

What is the stated purity?

The Core Peptides product listing specifies a stated purity of >99%.

Is the 10mg quantity a human dosage?

No. The 10mg figure describes the amount of research material supplied and is not a recommendation for human administration.

Does research prove that the blend is synergistic?

No. The different receptor pathways provide a scientific rationale for investigating potential complementary activity, but direct evidence for synergy in this exact commercial formulation remains limited.

Is this product an approved medicine?

No. It is presented as an experimental research peptide blend and should not be represented as an approved medicinal product or established treatment.

---

CJC-1295 & Ipamorelin Blend (10mg) Research Summary

CJC-1295 & Ipamorelin Blend (10mg) is an experimental two-peptide formulation containing equal quantities of CJC-1295 No DAC and Ipamorelin. The referenced product contains 5mg of each peptide, for a total of 10mg, and is supplied as a lyophilised powder with a stated purity above 99%.

CJC-1295 No DAC is investigated in relation to GHRH receptor signalling, while Ipamorelin is studied as a growth-hormone secretagogue associated with GHS-R1a. These distinct pathways provide a scientific basis for investigating how different upstream signals influence pituitary growth-hormone regulation.

The combination is therefore relevant to experimental research involving pituitary biology, growth-hormone signalling, GHRH receptors, GHS-R1a receptors and peptide pharmacology. Nevertheless, direct research on the exact commercial blend remains limited, so findings concerning individual components or related peptide combinations should not be presented as proof of clinical efficacy or safety.

---

Research-Use Disclaimer

CJC-1295 & Ipamorelin Blend (10mg) is intended for laboratory and research use only. It is not a medicine, dietary supplement, food product or approved therapeutic treatment.

The information provided in this product description is intended for scientific and educational purposes. It summarises research associated with the individual peptide components and their respective signalling pathways and should not be interpreted as evidence that this blend can diagnose, treat, cure or prevent any disease or medical condition.

Research findings involving individual peptides, different CJC-1295 preparations or other experimental combinations should not automatically be attributed to this exact 10mg formulation.

This description does not provide instructions for human administration, dosing, injection, reconstitution for human use or self-experimentation. Researchers should consult relevant scientific literature, batch-specific analytical documentation, institutional procedures and applicable laws and regulations when working with experimental peptide materials.